Sosei Group Corporation
4F Ichiban-cho FS Building
8 Ichiban-cho, Chiyoda-ku
78 articles with Sosei Group Corporation
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
Sosei Group Corporation (“the Company”; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
Sosei Group Corporation (“the Company”; TSE: 4565), today announce the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial.
Sosei Group Corporation will announce its earnings results and present operational highlights for the 6 months ended 30 June 2022 on Wednesday, 10 August 2022.
Sosei Group Corporation announces it has expanded its UK R&D operations into a second site within Granta Park, Cambridge, to The Cori Building, previously occupied by Cancer Research UK.
Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery
Sosei Group Corporation, the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases.
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2022.
Sosei Heptares to Embed Agile Operating Model and Enhance its Translational Medicine Capabilities through Strategic Collaboration with Weatherden
Sosei Group Corporation announces a strategic collaboration with Weatherden, a pioneering clinical development consulting group.
Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution
Sosei Group Corporation confirms that a series of Executive Management changes have been approved at the Company’s 32nd Shareholders’ Meeting today and are effective immediately.
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2021.
Sosei Group Corporation Proposes Changes to its Leadership Team as Part of Succession Plan to Drive the Company Through the Next Stage of its Evolution
Sosei Group Corporation, announces that its Board of Directors approved the nomination of candidates for its Representative Executive Officer, Directors and Executive Officers as stated below.
Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2021 on Thursday, 10 February 2022.
Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseases
Sosei Group Corporation and Verily, an Alphabet precision health company, announced they have entered into a strategic research collaboration.
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
Sosei Group Corporation, announced its Chief Financial Officer, Chris Cargill, will present at the 40th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Monday, January 10, 2022.
Sosei Group Corporation announces that in connection with the Collaboration and License Agreement with Neurocrine Biosciences, Inc. announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on 22 December 2021.
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets
Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares.
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023.
Under the strategic collaboration, Neurocrine Biosciences and Sosei Group Corporation will develop and commercialize novel muscarinic receptor agonists to treat the said illnesses.
Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven
Sosei Group Corporation announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study.
Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
Ninth GPCR-targeted drug candidate overall generated from Sosei Heptares' StaR® technology/SBDD platform to enter clinical development